Loading...
XETR
GXI
Market cap2.04bUSD
Apr 17, Last price  
51.85EUR
1D
2.07%
1Q
-22.61%
Jan 2017
-26.57%
IPO
35.03%
Name

Gerresheimer AG

Chart & Performance

D1W1MN
No data to show
P/E
16.32
P/S
0.88
EPS
3.18
Div Yield, %
2.41%
Shrs. gr., 5y
1.92%
Rev. gr., 5y
7.90%
Revenues
2.04b
+2.28%
00957,700,0001,060,103,0001,000,227,0001,024,804,0001,094,681,0001,219,068,0001,265,931,0001,290,016,0001,377,232,0001,375,460,0001,348,255,0001,367,730,0001,392,255,0001,418,786,0001,498,007,0001,817,094,0001,990,486,0002,035,903,000
Net income
110m
-5.52%
00-1,228,0004,510,0006,962,00046,747,00054,428,00060,191,00062,155,00066,336,000104,217,000121,638,000100,887,000128,965,00080,781,00088,559,00083,788,00096,120,000116,126,000109,720,000
CFO
240m
-18.35%
36,821,00054,747,00054,108,000165,333,000117,466,000159,787,000129,747,000173,566,000146,676,000158,286,000203,776,000173,487,000219,163,000173,472,000192,924,000222,194,000212,076,000221,941,000294,337,000240,332,000
Dividend
Jun 06, 20250 EUR/sh
Earnings
Jun 05, 2025

Profile

Gerresheimer AG, together with its subsidiaries, manufactures and sells packaging products, and drug delivery-devices and solutions worldwide. It operates through Plastics & Devices, Primary Packaging Glass, and Advanced Technologies divisions. The Plastics & Devices division offers drug delivery systems, including inhalers, insulin pen systems, prefillable syringes, and diagnostic systems for the pharma, biotech, diagnostics, and medical technology industries; containers and closures, PET bottles, eye droppers, nasal sprays, nebulizers, applicators, and accessories for solid, liquid, and ophthalmic applications; and bottles and containers for nutritional supplements. The Primary Packaging Glass division offers glass primary packaging for pharma and cosmetics industries, such as infusion, dropper, and syrup bottles; injection vials, ampoules, and cartridges; miniature bottles and glass containers for liquid food, spices, and spirits; and packaging solutions for fragrances, deodorants, skin care, and wellness products, as well as beauty and pharmaceutical products. The Advanced Technologies division develops smart drug delivery systems, such as micro pumps, which are used to self-administer medication for Parkinson's disease or heart failure to pharmaceutical and biotech customers. The company was founded in 1864 and is headquartered in Düsseldorf, Germany.
URL
https://www.gerresheimer.com/
IPO date
Jun 11, 2007
Employees
11,234
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑112023‑112022‑112021‑112020‑112019‑112018‑112017‑112016‑112015‑11
Income
Revenues
2,035,903
2.28%
1,990,486
9.54%
1,817,094
21.30%
Cost of revenue
1,792,262
1,784,757
1,901,175
Unusual Expense (Income)
NOPBT
243,641
205,729
(84,081)
NOPBT Margin
11.97%
10.34%
Operating Taxes
34,496
47,344
38,620
Tax Rate
14.16%
23.01%
NOPAT
209,145
158,385
(122,701)
Net income
109,720
-5.52%
116,126
20.81%
96,120
14.72%
Dividends
(45,298)
(39,250)
Dividend yield
Proceeds from repurchase of equity
271,610
BB yield
Debt
Debt current
366,110
382,813
535,717
Long-term debt
981,564
721,255
748,062
Deferred revenue
122,187
94,626
19,482
Other long-term liabilities
129,903
131,867
115,896
Net debt
1,103,196
966,493
1,144,143
Cash flow
Cash from operating activities
240,332
294,337
221,941
CAPEX
(369,846)
(328,037)
(238,074)
Cash from investing activities
(345,586)
(307,432)
(256,181)
Cash from financing activities
168,269
40,348
44,239
FCF
(26,047)
(122,454)
(322,852)
Balance
Cash
213,059
122,339
124,834
Long term investments
31,419
15,236
14,802
Excess cash
142,683
38,051
48,781
Stockholders' equity
808,331
742,410
755,548
Invested Capital
2,930,745
2,702,117
2,541,090
ROIC
7.43%
6.04%
ROCE
7.64%
7.21%
EV
Common stock shares outstanding
34,540
33,336
31,400
Price
Market cap
EV
EBITDA
442,173
391,755
87,474
EV/EBITDA
Interest
60,625
50,435
27,955
Interest/NOPBT
24.88%
24.52%